undefined

MRK
Exchange NYQ, Currency in USD
Loading price...

Overview

Previous Close129.79
Open128.92
Ask132.00
Bid128.80
Day's Range128.14 - 131.04
52 Week Range77.58 - 135.05
PE Ratio(TTM)36.68
Market Cap--
Volume4.65M
Avg. Volume10.04M
12 Months Earnings8.94B
12 Months Revenue65.77B

Performance

ABSCAGR
YTD1 Month3 Months1 Year2 Years5 Years10 Years
No results to display

Profit/Loss

PARTICULARSTTM20252025202420232022
Operating Revenue65.77B65.01B63.62B64.17B60.12B59.28B
Cost of Revenue17.16B16.38B14.88B15.19B16.13B17.41B
Gross Profit48.61B48.63B48.73B48.98B43.99B41.87B
Operating Expenses35.64B26.52B28.91B28.75B41.03B23.59B
Profit after Tax (Net Income)8.94B18.25B16.41B17.12B365.00M14.52B

Company Profile

Sector: Healthcare
Industry: Drug Manufacturers - General
HQ Location: Rahway, United States
Website: https://www.merck.com
Chairman, President & CEO: Mr. Robert M. Davis J.D.
Employees: 73,000
About Company:
Merck & Co., Inc. operates as a healthcare company worldwide. It offers human health pharmaceutical for various areas under the Keytruda, Keytruda Qlex, Welireg, Gardasil, ProQuad, M-M-R II, Varivax, Vaxneuvance, Capvaxive, RotaTeq, Pneumovax 23, Bridion, Prevymis, Dificid, Zerbaxa, Winrevair, Adempas/ Verquvo, Ohtuvayre, Lagevrio, Isentress/Isentress HD, Delstrigo, Pifeltro, Belsomra, Januvia, and Janumet brands. The company also provides veterinary pharmaceuticals, vaccines and health management solutions and services, such as livestock products under the Nuflor, Bovilis/Vista, Bovilis Cryptium, Banamine, Estrumate, Matrix, Resflor, Zuprevo, Revalor, Safe-Guard, M+Pac, Porcilis, Circumvent, Nobilis/Innovax, Paracox and Coccivac, Exzolt, Slice, Imvixa, Clynav, Aquavac/Norvax, Aquaflor, Flexolt brands; Allflex Livestock Intelligence solutions; and companion animal products under the Bravecto One-Month, Bravecto Injectable/Quantum, Bravecto TriUNO, Bravecto Plus, Sentinel Spectrum, Sentinel Flavor Tabs, Numelvi, Optimmune, Nobivac NXT, GilvetMab, Otomax, Mometamax, Mometamax Ultra, Posatex, Caninsulin/Vetsulin, Panacur, Safeguard, Regumate, Prestige, Scalibor/Exspot, Sure Petcare, and Home Again brands. It has development and commercialization agreement for three of Daiichi Sankyo's deruxtecan ADC candidates; AstraZeneca PLC to co-development and co-commercialize AstraZeneca's Lynparza products for multiple cancer types; licensed to develop, manufacture and commercialize LM-299, a novel investigational PD-1/VEGF bispecific antibody from LaNova; and collaboration agreement with Eisai Co., Ltd., Bayer AG, and Ridgeback Biotherapeutics LP, as well Moderna, Inc. Merck & Co., Inc. has strategic collaboration with Infinimmune, Inc. to discover and develop antibodies against multiple therapeutic targets. The company was founded in 1891 and is headquartered in Rahway, New Jersey.